PA
SLAB icon

PharVision Advisers’s Silicon Laboratories SLAB Stock Holding History

PharVision Advisers’s Portfolio SLAB Stock Details SLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,877
Closed -$246K – 976
2025
Q3 		$246K Buy
+1,877
New +$256K 0.14% 344

Other funds holding SLAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PharVision Advisers's SLAB Position: Q4 2025 in Review

PharVision Advisers sold out of Silicon Laboratories (SLAB) in Q4 2025, closing a stake of 1,877 shares — an estimated $246K sold.

PharVision Advisers first reported a position in SLAB in Q3 2025 and held it in 1 quarter. The position peaked at $246K in Q3 2025. 326 funds tracked by Wall St. Rank hold SLAB as of Q4 2025.

  • PharVision Advisers reported no remaining Silicon Laboratories position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 1,877 Silicon Laboratories shares in Q4 2025, an estimated $246K.
  • PharVision Advisers first reported a position in Silicon Laboratories in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Silicon Laboratories position peaked at $246K in Q3 2025.
  • 326 funds tracked by Wall St. Rank held Silicon Laboratories as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.